Dapagliflozin: A review of its use in patients with type 2 diabetes

Drugs

Volumn 74, Issue 18, 2014, Pages 2191-2209

  Plosker, Greg L ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DAPAGLIFLOZIN; DAPAGLIFLOZIN PLUS METFORMIN; GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER;

ADD ON THERAPY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; CONSTIPATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE GENITAL TRACT INFECTION; FOLLOW UP; FRACTURE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFLUENZA; INSULIN RELEASE; KIDNEY DYSFUNCTION; MALE GENITAL TRACT INFECTION; MAXIMUM PLASMA CONCENTRATION; MICTURITION DISORDER; MONOTHERAPY; MYCOSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; RHINOPHARYNGITIS; RISK ASSESSMENT; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY FREQUENCY; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; KIDNEY TUBULE ABSORPTION; METABOLISM; TREATMENT OUTCOME; URINARY EXCRETION;

BENZHYDRYL COMPOUNDS; BIOLOGICAL AVAILABILITY; BODY WEIGHT; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; RENAL ELIMINATION; RENAL REABSORPTION; SODIUM-GLUCOSE TRANSPORT PROTEINS; TREATMENT OUTCOME;

EID: 84915747765     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0324-3     Document Type: Article

References (103)

1. International Diabetes Federation. IDF Diabetes Atlas, 6th Edition. 2013. http://www.idf.org/diabetesatlas. Accessed 12 Aug 2014.
2. International Diabetes Federation. Global Diabetes Plan 2011-2021. 2011. http://www.idf.org/sites/default/files/Global-Diabetes-Plan-Final.pdf. Accessed 12 Aug 2014.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-79.
4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014; 37(Suppl 1): S81-90.
5. American Diabetes Association. Standards of medical care in diabetes: 2014. Diabetes Care. 2014; 37(Suppl 1): S14-80.
6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-12.
7. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005-12.
8. Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(17):2289-312.
9. Forxiga (dapagliflozin) tablets for oral use: US prescribing information. 2014. http://www1.astrazeneca-us.com/pi/pi-farxiga.pdf#page=1. Accessed 22 Oct 2014.
10. European Medicines Agency. Forxiga 5 and 10 mg film-coated tablets: summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002322/WC500136026.pdf. Accessed 22 October 2014.
11. Kasichayanula S, Liu X, Lacreta F, et al. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014;53(1):17-27.
12. Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010;70(4):377-85.
13. Bakris GL, Fonseca VA, Sharma K, et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75(12):1272-7.
14. Thomas MC. Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2014;5(3):53-61.
15. Mudaliar S, Henry RR, Boden G, et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther. 2014;16(3):137-44.
16. Weir GC, Marselli L, Marchetti P, et al. Towards better understanding of the contributions of overwork and glucotoxicity to the beta-cell inadequacy of type 2 diabetes. Diabetes Obes Metab. 2009; 11(Suppl 4): 82-90.
17. Devenny JJ, Godonis HE, Harvey SJ, et al. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity. 2012;20(8):1645-52.
18. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124(2):509-14.
19. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499-508.
20. Bonner C, Kerr-Conte J, Gmyr V et al. Glucose transporter SGLT2 inhibition triggers glucagon secretion in alpha cells [abstract no. 609]. Diabetologia. 2014; 57(Suppl 1): S251-2.
21. Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010;38(3):405-14.
22. Boulton DW, Kasichayanula S, Keung CF, et al. Simultaneous oral therapeutic and intravenous 14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br J Clin Pharmacol. 2013;75(3):763-8.
23. Kasichayanula S, Liu X, Zhang W, et al. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obes Metab. 2011;13(8):770-3.
24. Kasichayanula S, Liu X, Zhang W, et al. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clinical Ther. 2011;33(11):1798-808.
25. Kasichayanula S, Chang M, Hasegawa M, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(4):357-65.
26. Yang L, Li H, Li H et al. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. Clin Ther. 2013; 35(8): 1211-22.e2.
27. Kasichayanula S, Chang M, Liu X, et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012;29(2):163-77.
28. Scheen AJ. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. Clin Pharmacokinet. 2014;53(4):295-304.
29. Imamura A, Kusunoki M, Ueda S, et al. Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes. Diabetes Ther. 2013;4(1):41-9.
30. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223-33.
31. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015-22.
32. Rosenstock J, Vico M, Wei L. Effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473-8.
33. Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928-38.
34. Wilding JPH, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin a randomized trial. Ann Intern Med. 2012;156(6):405-15.
35. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217-24.
36. Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66(5):446-56.
37. Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37(3):740-50.
38. Matthaei S, Bowering K, Rohwedder K, et al. Improvement in glycemic control and reduction in body weight over 52 weeks with dapagliflozin as add-on therapy to metformin plus sulfonylurea [abstract no. 267-OR]. Diabetes. 2014; 63(Suppl 1): A70-1.
39. Hansen L, Zee P, Li Y et al. Randomised, double-blind trial of dual add-on saxagliptin plus dapagliflozin vs. Saxagliptin or dapagliflozin add-on alone in poorly controlled type 2 diabetes on metformin [abstract no. 4]. Diabetologia. 2014; 57(Suppl 1): S8.
40. Bailey CJ, Gross JL, Hennicken D et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013; 11(1).
41. Del Prato S, Nauck M, Duran-Garcia S et al. Durability of dapagliflozin vs. glipizide as add-on therapies in T2DM inadequately controlled on metformin: 4-year data [abstract no. 62-LB]. Diabetes. 2013; 62(Suppl 1A): LB17.
42. Strojek K, Yoon K-H, Hruba V, et al. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther. 2014;5(1):267-83.
43. Wilding JPH, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16(2):124-36.
44. Nauck MA, Del Prato S, Duran-Garcia S, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus was inadequately controlled with metformin. Diabetes Obes Metab. 2014;16(11):1111-20.
45. Del Prato S, Nauck M, Rohwedder K et al. Durability of glycaemic response with dapagliflozin as add-on therapy in type 2 diabetes inadequately controlled with metformin: 4-year data versus glipizide [abstract]. Diabetologia. 2014; 57(1)Suppl: 345.
46. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020-31.
47. Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16(2):159-69.
48. Grandy S, Langkilde AM, Sugg JE, et al. Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years. Int J Clin Pract. 2014;68(4):486-94.
49. Grandy S, Hashemi M, Langkilde AM, et al. Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab. 2014;16(7):645-50.
50. Grandy S, Ryden A, Sugg J et al. Weight-related quality of life and treatment satisfaction among type 2 diabetes mellitus patients treated with dapagliflozin in triple-therapy regimen [abstract no. 802-P]. Diabetes. 2014; 63(Suppl 1): A204-5.
51. Sun YN, Zhou Y, Chen X et al. The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials. BMJ Open. 2014; 4(4).
52. Orme M, Fenici P, Duprat Lomon I et al. A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy. Diabetol Metab Syndr. 2014; 6(1): 73.
53. Zhang M, Zhang L, Wu B, et al. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014;30(3):204-21.
54. Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab. 2014;16(5):433-42.
55. European Medicines Agency. Xigduo film-coated tablets: summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002672/WC500161033.pdf. Accessed 23 Oct 2014.
56. U.S. FDA approves once-daily Xigduo XR tablets for adults with type 2 diabetes. http://www.astrazeneca-us.com/media/press-releases/Article/20141030-us-fda-approves-oncedaily-xigduo-xr-tablets. Accessed 31 Oct 2014
57. Leiter LA, Cefalu WT, de Bruin TW, et al. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with pre-existing cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014;62(7):1252-62.
58. Gause-Nilsson I, de Bruin TW, Sugg JE et al. Two-year efficacy and safety of dapagliflozin for T2DM patients with a history of cardiovascular disease [abstract no. 1050-P]. Diabetes. 2014; 63(Suppl 1): A271.
59. Cefalu WT, Gause-Nilsson IA, De Bruin TW et al. Long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes, cardiovascular disease, and hypertension [abstract no. 1099-P]. Diabetes. 2014; 63(Suppl 1): A286.
60. Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962-71.
61. Kaku K, Inoue S, Matsuoka O, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2013;15:432-40.
62. Kaku K, Kiyosue A, Inoue S, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab. 2014;16(11):1102-10.
63. Ji L, Ma J, Li H et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014; 36(1): 84-100.e9.
64. Ji L, Li H, Mansfield T et al. Dapagliflozin as monotherapy in a Chinese population of drug-naïve patients with type 2 diabetes [abstract no. PD-0708]. In: World Diabetes Congress; 2-6 Dec 2013; Melbourne.
65. Kaku K, Maegawa H, Tanizawa Y, et al. Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Diabetes Ther. 2014. doi: 10.1007/s13300-014-0086-7.
66. Yang W, Han P, Liu B et al. Dapagliflozin (DAPA) reduces HbA1c in Asian patients with T2DM after metformin (MET) failure [abstract no. 1076-P]. Diabetes. 2014; 63(Suppl 1): A279.
67. Katz A, Yeh H, Sugg J et al. Efficacy of dapagliflozin in patients with type 2 diabetes mellitus and baseline HbA1c = 9.0 % [abstract no. 1094-P]. Diabetes. 2014; 63(Suppl 1): A284-5.
68. Fioretto P, De Bruin T, Johnsson E et al. Safety and efficacy of the SGLT2 inhibitor dapagliflozin in older patients with type 2 diabetes [abstract no. 954]. Diabetologica. 2013; 56(Suppl 1): S383.
69. Sjostrom D, Ptaszynska A, List J et al. Dapagliflozin lowers blood pressure in patients with type 2 diabetes [abstract no. 2418-PO]. Diabetes. 2014; 63(Suppl 1): A613.
70. Weber MA, Mansfield TA, Alessi F et al. Effects of dapagliflozin on blood pressure in diabetic patients with hypertension inadequately controlled by a renin-angiotensin system blocker [abstract no. 13144]. Circulation. 2013; 128 Suppl.(22).
71. Weber MA, Mansfield TA, T'Joen C et al. Dapagliflozin for reduction of blood pressure in diabetic patients inadequately controlled with combination antihypertensive regimen [abstract no. 13165]. Circulation. 2013; 128 Suppl.(22).
72. Woo V, Leiter LA, Cefalu WT et al. Blood pressure reduction with dapagliflozin in patients with type 2 diabetes and cardiovascular disease [abstract no. 10606]. Circulation. 2013; 128 Suppl.(22).
73. Lambers Heerspink HJ, de Zeeuw D, Wie L et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013; 15(9): 853-62.
74. Geerlings S, Fonseca V, Castro-Diaz D, et al. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103(3):373-81.
75. Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complic. 2013;27(5):479-84.
76. Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complic. 2013;27(5):473-8.
77. Rohwedder K, Parikh SJ, Johnsson E. Lower risk of hypoglycemic events with dapagliflozin than glipizide over 4 years in a phase 3 study [abstract no. 2218-PO]. Diabetes. 2014; 63(Suppl 1): A563-4.
78. Ptaszynska A, Mansfield T, Johnsson E et al. Long-term renal safety with dapagliflozin treatment [abstract no. 1036-P]. Diabetes. 2014; 63(Suppl 1): A267.
79. Thomson SC, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012;302(1):R75-83.
80. Johnsson K, Johnsson E, Mansfield T et al. Diuresis-related safety and tolerability of dapagliflozin (DAPA) in T2DM over 24 weeks [abstract no. 1031-P]. Diabetes. 2014; 63(Suppl 1): A265.
81. de Bruin TW, Leiter LA, Cefalu WT, et al. Dapagliflozin in patients with type 2 diabetes and established cardiovascular disease: hypotension and volume-related safety [abstract no. 10677]. Circulation. 2013;128(Suppl):1.
82. Hardy E, Ptaszynska A, de Bruin T, et al. Changes in lipid profiles of patients with type 2 diabetes millitus on dapagliflozin therapy [abstract no. 947]. Diabetologia. 2013;56(Suppl. 1):S379.
83. Sonesson C, Frederich R, Johansson PA, et al. Cardiovascular safety of dapagliflozin in type 2 diabetes mellitus (T2DM) patients with various degrees of cardiovascular risk [abstract no. P6094]. Eur Heart J. 2014;35(Suppl. 1):1072.
84. ClinicalTrials.gov. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardivascular events (DECLARE-TIMI58). 2014. http://clinicaltrials.gov/show/NCT01730534. Accessed 5 Sep 2014.
85. Ljunggren O, Bolinder J, Johansson L et al. Dapagliflozin has no long-term effect on markers of bone turnover or bone mineral density in patients with inadequately controlled type 2 diabetes on metformin [abstract]. Diabetologia. 2012; 55(Suppl 1): 748.
86. Ptaszynska A, Mansfield T, Apanovich AM et al. Dapagliflozin, selective SGLT2 inhibitor, does not increase risk of fractures [abstract no. 1085-P]. Diabetes. 2014; 63(Suppl 1): A282.
87. Yavin Y, Mansfield T, Ptaszynska A et al. Hyperkalemia incidence with the SGLT2 inhibitor dapagliflozin [abstract no. 1086-P]. Diabetes. 2014; 63(Suppl 1): A282.
88. Reilly TP, Graziano MJ, Janovitz EB, et al. Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2014;5(1):73-96.
89. Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2014. doi: 10.1016/S2213-8587(14)70004-X.
90. Barnett AH. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad Med. 2013;125(5):92-100.
91. Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(7):807-24.
92. Henry RR, Rosenstock J, Chalamandaris A-G, et al. Exploring the potential of dapagliflozin in type 1 diabetes: phase 2a pilot study [abstract no. 992]. Diabetologia. 2013;56(Suppl 1):S398.
93. Kasichayanula S, Griffen SC, Chalamandaris A et al. Dapagliflozin, a selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 1 diabetes mellitus [abstract no. PI-008]. Clin Pharmacol Ther. 2014; 95(Suppl 1): S19-20.
94. Sabale U, Ekman M, Granstrom O, et al. Cost-effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Prim Care Diabetes. 2014. doi: 10.1016/j.pcd.2014.04.007.
95. Van Haalen HGM, Pompen M, Bergenheim K, et al. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Investig. 2014;34(2):135-46.
96. Bergenheim K, Grandy S, Wygant GD. Cost of achieving relevant composite endpoint of HbA1c < 7 %, no hypoglycaemia and weight loss of ≥3 % in a 52 week post-hoc analysis of dapagliflozin versus glipizide [abstract no. PDB45]. Value Health. 2013;16:A439.
97. Charokopou M, McEwan P, Lister S, et al. The cost-effectiveness of dapagliflozin (Forxiga) versus a DPP-4 inhibitor in the treatment of type 2 diabetes mellitus (T2DM) in England and Wales [abstract no. PDB54]. Value Health. 2013;16:A440.
98. Abad Paniagua EJ, Casado Escribano P, Fernandez Rodriguez JM et al. Cost-effectiveness analysis of dapaglifozin versus other T2DM treatments in the Spanish context [abstract no. PDB47]. Value Health. 2013; 16: A439.
99. Elgart JF, Prestes M, Gonzalez L, et al. Dapagliflozin versus sulfonylurea as an add-on therapy to metformin: a cost-effectiveness analysis in Colombia [abstract]. Value Health. 2014;17:A247.
100. Elgart JF, Prestes M, Gonzalez L, et al. Dapagliflozin: cost-effectiveness as an add-on therapy to metformin in the treatment of type 2 diabetes (T2DM) in Argentina and Chile [abstract]. Value Health. 2014;17:A248.
101. Gordon J, Bell K, Shah M, et al. Weight gain, hypoglycaemia and cost-effectiveness: what drives value among type 2 diabetes treatments in the short term [abstract]. Value Health. 2014;17:A251.
102. Gordon J, Bell K, Shah M, et al. Importance of longer-term follow-up data in estimating cost-effectiveness of new treatments for type 2 diabetes [abstract no. 1195-P]. Diabetes. 2014; 63(Suppl 1): A311.
103. Neslusan C, Teschemaker A, Martin S, et al. Cost-effectiveness analysis of canagliflozin (CANA) versus dapagliflozin (DAPA) as an add-on to metformin (MET) in patients with type 2 diabetes mellitus (T2DM) in the United States [abstract]. Value Health. 2014;17:A248.